维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02561 维昇药业-B

休市中 02-27 15:50:10

32.780

-0.100

-0.30%

最高32.880	最低32.100	成交量1,000
今开32.860	昨收32.880	日振幅2.37%
总市值37.37亿	流通市值37.37亿	总股本1.14亿
成交额3.23万	换手率0.00%	流通股本1.14亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维昇药业-B","latestPrice":32.78,"timestamp":1772178610453,"preClose":32.88,"halted":0,"volume":1000,"delay":0,"changeRate":-0.0030413625304136684,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"休市中","change":-0.1,"latestTime":"02-27 15:50:10","open":32.86,"high":32.88,"low":32.1,"amount":32338,"amplitude":0.023723,"askPrice":32.78,"askSize":1000,"bidPrice":32.22,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.087,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":7,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":32.88,"openAndCloseTimeList":[[1772155800000,1772164800000],[1772168400000,1772179200000]],"volumeRatio":0.08143322521989622,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02561/tweets","defaultTab":"tweets","newsList":[{"id":"2616810145","title":"儿童软骨发育不全新药获批，维升药业拥有大中华区权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2616810145","media":"医药时间","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616810145?lang=zh_cn&edition=full","pubTime":"2026-02-28 19:58","pubTimestamp":1772279913,"startTime":"0","endTime":"0","summary":"维升药业拥有那韦培肽在大中华区的独家开发、生产及商业化权利。此次批准是基于三项随机、双盲、安慰剂对照临床试验，以及长达三年的开放标签扩展研究数据，其中包括在软骨发育不全患儿中开展的关键性 ApproaCH 试验结果。在中国，软骨发育不全症已被纳入《第二批罕见病目录》，但目前国内尚无切实有效的治疗方法。在此背景下，那韦培肽有望填补治疗空白，改变中国软骨发育不全症的治疗格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228213302a72abaad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228213302a72abaad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2614008547","title":"每日卖空追踪 | 维升药业-B 02月26日卖空量成交900股，卖空比例为6.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614008547","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614008547?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:30","pubTimestamp":1772094632,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间02月26日，跌0.36%，卖空量成交900股，较上一交易日增加100%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163442a4cab5e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163442a4cab5e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2613753492","title":"每日卖空追踪 | 维升药业-B 02月23日卖空量成交500股，卖空比例为1.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613753492","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613753492?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:30","pubTimestamp":1771835431,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间02月23日，跌1.79%，卖空量成交500股，较上一交易日增加100%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163405a71564c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163405a71564c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2610937738","title":"维升药业-B02月11日主力净流出36.2万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2610937738","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610937738?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:16","pubTimestamp":1770797761,"startTime":"0","endTime":"0","summary":"02月11日, 维升药业-B股价跌0.60%，报收33.30元，成交金额113.0万元，换手率0.03%，振幅2.63%，量比3.25。维升药业-B今日主力资金净流出36.2万元，上一交易日主力净流出0万元。该股近5个交易日下跌0.54%，主力资金累计净流出36.2万元；近20日主力资金累计净流出218.9万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211162219a497233b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211162219a497233b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2609058472","title":"维升药业深化源头创新布局携手晶泰科技以AI赋能内分泌新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2609058472","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609058472?lang=zh_cn&edition=full","pubTime":"2026-02-05 18:41","pubTimestamp":1770288060,"startTime":"0","endTime":"0","summary":"2026年2月5日，维升药业与晶泰科技宣布达成项目协议及长期战略合作，合作规模达数千万元。维升药业旨在将晶泰科技AI技术深度整合至内分泌新药源头创新，聚焦高临床价值适应症与创新靶点，加速构建产品管线。此次合作是其在夯实内部研发、引进成熟管线基础上的精准布局，通过AI驱动突破传统研发瓶颈，为产品管线注入新动能。维升药业已构建全链条布局，认识到持续引领创新需挖掘新靶点、拓展适应症、迭代升级管线。内分泌代谢疾病机制复杂，传统研发模式挑战大，维升药业引入晶泰科技AI药物发现平台，双方合作将聚焦内分泌代谢领域，实现候选新分子早期发现和优化设计，系统性降低后续研发风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205190546a6d6ed2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205190546a6d6ed2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","02228","BK1141","BK1617","BK1161"],"gpt_icon":0},{"id":"1126602143","title":"维昇药业（2561）2026年1月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1126602143","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126602143?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:37","pubTimestamp":1770107820,"startTime":"0","endTime":"0","summary":"维昇药业（股票代码：2561）于2026年2月3日发布2026年1月股份变动月报。公告显示，截至1月31日，公司普通股注册股本维持在500,000,000股，面值每股USD 0.0001，注册股本总额USD 50,000。期末已发行普通股数量为113,926,864股，较上月底无新增发行或注销，库藏股数为零。\n报告期内，公司并无股份期权或可换股债券行使，无购回或注销记录。董事会确认公司公众持股量符合香港联交所相关要求。公告由执行董事卢安邦签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c948fb8095e6dfc21c5f65a8776294af","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":0},{"id":"2606209220","title":"隆培生长激素获批，维升药业-B(02561)估值增长打上“强心针”","url":"https://stock-news.laohu8.com/highlight/detail?id=2606209220","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606209220?lang=zh_cn&edition=full","pubTime":"2026-01-27 08:52","pubTimestamp":1769475131,"startTime":"0","endTime":"0","summary":"1月26日，港股创新药企维升药业-B给出了答案：其核心产品隆培生长激素于近日正式获国家药监局上市批准。目前，维升药业已在中国完成其用于治疗3至17岁儿童生长激素缺乏症的3期关键性试验。伴随隆培生长激素未来获批上市及其他在研管线向前推进，公司将进入全面加速发展的新阶段，步入收获期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"隆培生长激素获批，维升药业-B(02561)估值增长打上“强心针”","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2606335223","title":"国内第四款长效生长激素获批，如何搅动百亿市场竞争格局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2606335223","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606335223?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:32","pubTimestamp":1769437951,"startTime":"0","endTime":"0","summary":"国内生长激素领域又迎来新选手。这是国内获批的第四款长效生长激素，也是国内首个且目前唯一经三期临床证实优效于日制剂的长效生长激素。此外，国内长效生长激素市场规模预计将在两年内超过短效产品，并在2030年占据全市场80%的份额。此次隆培生长激素在国内获批是基于一项3期关键性试验。维升药业相关负责人认为，真正使用生长激素的患者，绝大多数仍然是自费，早已进入医保的短效生长激素就是如此。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126223623a4581e52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126223623a4581e52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2606211537","title":"维升药业-B(02561)：注射用隆培生长激素的生物制品上市许可申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2606211537","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606211537?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:45","pubTimestamp":1769424332,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B 发布公告，中国国家药品监督管理局已批准注射用隆培生长激素的生物制品上市许可申请，用于在中国治疗3岁及以上儿童及青少年的生长激素缺乏症所致的生长缓慢。此新药获批上市主要依据于中国完成对3至17岁儿童生长激素缺乏症患者的3期关键性试验。隆培生长激素获BLA批准后，集团已启动全面商业化计划，以确保供应并扩大市场覆盖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维升药业-B(02561)：注射用隆培生长激素的生物制品上市许可申请获国家药监局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2606238102","title":"维升药业-B盘中异动 大幅上涨5.25%报39.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606238102","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606238102?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:52","pubTimestamp":1769413972,"startTime":"0","endTime":"0","summary":"2026年01月26日临近收盘15时52分，维升药业-B股票出现异动，股价快速拉升5.25%。截至发稿，该股报39.700港元/股，成交量2.9万股，换手率0.03%，振幅5.25%。资金方面，该股资金流入83.2472万港元，流出19.8304万港元。维升药业-B股票所在的生物技术行业中，整体跌幅为2.15%。其相关个股中，北海康成-B、维亚生物、中生北控生物科技涨幅较大，振幅较大的相关个股有北海康成-B、中生北控生物科技、维亚生物，振幅分别为19.48%、17.28%、15.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126155252a4569304&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126155252a4569304&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2605342821","title":"港股异动 | 维升药业-B(02561)盘中涨超9% 核心产品隆培促生长素预计即将获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2605342821","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605342821?lang=zh_cn&edition=full","pubTime":"2026-01-23 11:52","pubTimestamp":1769140357,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B(02561)盘中涨超9%，截至发稿，涨7.13%，报37.24港元。消息面上，据Insight数据库显示，维升药业-B核心产品隆培促生长素已于2026年1月12日离开补充资料任务，预计即将获批。据公开资料显示，隆培促生长素是维升药业-B从Ascendis Pharma引进的长效生长激素前药，基于TransCon暂时连接技术研发，用于治疗儿童生长激素缺乏症(GHD)，每周皮下注射一次，可释放未经修饰的天然人生长激素，欧美此前已获批。国内生长激素市场以日制剂为主，周制剂可大幅提升患者依从性，上市后有望重塑竞争格局，满足未被充分满足的临床需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 维升药业-B(02561)盘中涨超9% 核心产品隆培促生长素预计即将获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1610","BK1161","02561"],"gpt_icon":0},{"id":"2603661929","title":"维升药业-B01月14日主力净流入15.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2603661929","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603661929?lang=zh_cn&edition=full","pubTime":"2026-01-14 16:16","pubTimestamp":1768378573,"startTime":"0","endTime":"0","summary":"01月14日, 维升药业-B股价涨2.27%，报收34.28元，成交金额115.2万元，换手率0.03%，振幅5.67%，量比1.16。维升药业-B今日主力资金净流入15.9万元，上一交易日主力净流出0万元。该股近5个交易日下跌2.00%，主力资金累计净流入77.4万元；近20日主力资金累计净流出74.4万元，其中净流出天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114162621a4c25e56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114162621a4c25e56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2603468687","title":"每日卖空追踪 | 维升药业-B 01月13日卖空量成交100股，卖空比例为0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603468687","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603468687?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:30","pubTimestamp":1768293031,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间01月13日，涨0.18%，卖空量成交100股，较上一交易日减少66.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113164444a714fd85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113164444a714fd85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2602548248","title":"每日卖空追踪 | 维升药业-B 01月12日卖空量成交300股，卖空比例为2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548248","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602548248?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:30","pubTimestamp":1768206630,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间01月12日，跌0.65%，卖空量成交300股，较上一交易日减少66.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112164944a710ca0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112164944a710ca0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2602373703","title":"每日卖空追踪 | 维升药业-B 01月09日卖空量成交400股，卖空比例为0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602373703?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:30","pubTimestamp":1767947431,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间01月09日，跌0.24%，卖空量成交400股，较上一交易日减少55.56%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163840a7067e50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163840a7067e50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2601809917","title":"每日卖空追踪 | 维升药业-B 01月07日卖空量成交1000股，卖空比例为3.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601809917","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601809917?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:30","pubTimestamp":1767774632,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间01月07日，涨0.46%，卖空量成交1000股，较上一交易日增加150%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163455a4a6e725&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163455a4a6e725&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"1139259482","title":"维昇药业（02561）2025年12月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1139259482","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139259482?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:37","pubTimestamp":1767688642,"startTime":"0","endTime":"0","summary":"维昇药业于2026年1月6日发布截至2025年12月31日的股份变动月报表。公告显示，公司本月未有新增发行、购回或注销股份，股本结构保持稳定。\n\\n\\n根据报告，公司注册股本维持在 500,000,000 股，面值每股0.0001美元，对应注册股本总额50,000美元；已发行股份（不含库存股）维持113,926,864股，与上月末保持一致，库存股数量仍为0股，未发生任何变动。\n\\n\\n公告同时提及根据股东大会通过的股份激励计划，截至本月并无新股因该计划而发行。公司称其已遵守香港联交所《上市规则》及相关法律法规。\n\\n\\n本次月报由执行董事盧安邦签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":0},{"id":"2600706669","title":"每日卖空追踪 | 维升药业-B 12月31日卖空量成交600股，卖空比例为2.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600706669","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600706669?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:30","pubTimestamp":1767169831,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间12月31日，跌2.09%，卖空量成交600股，较上一交易日减少33.33%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231163448a48dc7d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231163448a48dc7d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2595715831","title":"维升药业-B12月30日遭主力抛售16.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595715831","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595715831?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:15","pubTimestamp":1767082553,"startTime":"0","endTime":"0","summary":"12月30日, 维升药业-B股价跌4.61%，报收33.50元，成交金额150.2万元，换手率0.04%，振幅2.85%，量比1.55。维升药业-B今日主力资金净流出16.5万元，上一交易日主力净流出32.6万元。该股近5个交易日下跌5.63%，主力资金累计净流出134.6万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出89.5万元，其中净流出天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230162129a4897033&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230162129a4897033&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2595247754","title":"每日卖空追踪 | 维升药业-B 12月29日卖空量成交200股，卖空比例为0.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595247754","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595247754?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:30","pubTimestamp":1766997030,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间12月29日，跌3.3%，卖空量成交200股，较上一交易日增加100%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163453a6dc4a34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163453a6dc4a34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.visenpharma.com","stockEarnings":[{"period":"1week","weight":-0.0244},{"period":"1month","weight":-0.0688},{"period":"3month","weight":0.0657},{"period":"6month","weight":-0.2824},{"period":"1year","weight":-0.5235},{"period":"ytd","weight":-0.0006}],"compareEarnings":[{"period":"1week","weight":0.0082},{"period":"1month","weight":-0.043},{"period":"3month","weight":0.0298},{"period":"6month","weight":0.0619},{"period":"1year","weight":0.1228},{"period":"ytd","weight":0.039}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"维昇药业是一家主要从事开发并商业化颠覆式内分泌疗法的投资控股公司。该公司的主要在研产品包括隆培促生长素、那韦培肽和帕罗培特立帕肽。隆培促生長素用于治疗3至17岁儿童生长激素缺乏症患者。那韦培肽是一款用于治疗2至10岁软骨发育不全儿童患者的疾病修复疗法。帕罗培特立帕肽是一款用于治疗成人甲状旁腺功能减退症的治疗方法。该公司处于研发后期、产品接近商业化。","exchange":"SEHK","name":"维昇药业-B","nameEN":"VISEN PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维昇药业-B,02561,维昇药业-B股票,维昇药业-B股票老虎,维昇药业-B股票老虎国际,维昇药业-B行情,维昇药业-B股票行情,维昇药业-B股价,维昇药业-B股市,维昇药业-B股票价格,维昇药业-B股票交易,维昇药业-B股票购买,维昇药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}